ImmunoBrain Checkpoint
Ness Ziona, Israel· Est.
Israeli biotech harnessing peripheral immune modulation to treat Alzheimer’s disease with an anti‑PD‑L1 antibody.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Israeli biotech harnessing peripheral immune modulation to treat Alzheimer’s disease with an anti‑PD‑L1 antibody.
NeurodegenerationAlzheimer's disease
Technology Platform
Peripheral immune checkpoint modulation using anti‑PD‑L1 antibodies to reprogram systemic immune cells and reduce neuroinflammation.
Opportunities
A novel peripheral‑immune mechanism could differentiate IBC from existing CNS‑targeted AD therapies and enable expansion into other neurodegenerative diseases.
Risk Factors
Uncertainty around clinical efficacy in humans and the need for substantial funding to advance through later‑stage trials.
Competitive Landscape
Competes with anti‑amyloid and anti‑tau antibodies; differentiation lies in targeting peripheral immune checkpoints rather than direct CNS targets.